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ABSTRACT
Background
Obesity, the most common cause of insulin resistance, is increasingly recognized as a low-
grade inflammatory state. Adipocyte-derived resistin is a circulating protein implicated in
insulin resistance in rodents, but the role of human resistin is uncertain because it is produced
largely by macrophages.
Methods and Findings
The effect of endotoxin and cytokines on resistin gene and protein expression was studied in
human primary blood monocytes differentiated into macrophages and in healthy human
participants.
Inflammatory endotoxin induced resistin in primary human macrophages via a cascade
involving the secretion of inflammatory cytokines that circulate at increased levels in
individuals with obesity. Induction of resistin was attenuated by drugs with dual insulin-
sensitizing and anti-inflammatory properties that converge on NF-jB. In human study
participants, experimental endotoxemia, which produces an insulin-resistant state, causes a
dramatic rise in circulating resistin levels. Moreover, in patients with type 2 diabetes, serum
resistin levels are correlated with levels of soluble tumor necrosis factor a receptor, an
inflammatory marker linked to obesity, insulin resistance, and atherosclerosis.
Conclusions
Inflammation is a hyperresistinemic state in humans, and cytokine induction of resistin may
contribute to insulin resistance in endotoxemia, obesity, and other inflammatory states.
Introduction
Dietary and lifestyle changes during the last century have entailed an unprecedented
epidemic of obesity and associated metabolic diseases, including type 2 diabetes and
atherosclerosis [1]. Many individuals suffer simultaneously from more than one of these
conditions, and epidemiological studies in humans, as well as studies in animal models, suggest
that obesity-related insulin resistance is a common pathogenic feature [2]. Indeed, insulin
resistance is the keystone of the ‘‘metabolic syndrome,’’ a major cardiovascular risk factor even
in the absence of demonstrable glucose intolerance or diabetes [3]. Obesity and insulin
resistance are strongly associated with systemic markers of inﬂammation, and, indeed,
inﬂammation may contribute to insulin resistance [4]. Similarities and overlap between obesity
and inﬂammatory states are emerging. Inﬂammatory cytokines such as tumor necrosis factor a
(TNF a) and interleukin (IL)-6 are produced by adipocytes as well as by monocytes and
macrophages, and they circulate at increased levels in individuals with obesity [5,6]. Moreover,
bone-marrow-derived macrophages home in on adipose tissue in individuals with obesity [7,8],
and adipocytes and macrophages may even be interconvertible [9]. Furthermore, inﬂammation
is increasingly recognized as a major component and predictor of atherosclerotic vascular
disease, a major clinical consequence of insulin resistance [10]. Hence, the interrelationships
between obesity, insulin resistance, and atherosclerosis are of great scientiﬁc and clinical
interest.
We originally identiﬁed and characterized resistin as a circulating mouse adipocyte gene
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rodents, resistin is derived exclusively from adipocytes
[11,12], circulates at increased levels in obese animals [11],
and causes dysregulated hepatic glucose production, leading
to insulin resistance [13,14]. A syntenic gene exists in humans,
but is expressed at higher levels in monocytes and macro-
phages than in adipocytes [15,16], raising questions about the
relationship between resistin and human metabolic disease.
Recently, several studies have suggested that metabolic
abnormalities are associated with polymorphisms in the
human resistin gene [17,18]. Furthermore, several studies,
though not all, have reported increased serum resistin levels
in patients with obesity, insulin resistance, and/or type 2
diabetes [19,20,21,22,23,24,25,26]. However, the mechanism
and importance of increased resistin levels in human
metabolic disease are not known.
Here we show that the endotoxin lipopolysaccharide (LPS),
a potent inﬂammatory stimulant, dramatically increases
resistin production by inducing secretion of inﬂammatory
cytokines such as TNFa. This increase in resistin production
is blocked by both aspirin and rosiglitazone, drugs that have
dual anti-inﬂammatory and insulin-sensitizing actions and
have been shown to antagonize NF-jB. Indeed, activation of
NF-jB is sufﬁcient to induce resistin expression, and loss of
NF-jB function abolishes LPS induction of resistin. Resistin
serum levels are increased dramatically by endotoxemia in
humans, and correlate with a marker of inﬂammation in
patients with type 2 diabetes. Thus, systemic inﬂammation
leads to increased resistin production and circulating levels
in humans. The increased level of resistin in humans with
obesity is likely an indirect result of elevated levels of
inﬂammatory cytokines characteristic of states of increased
adiposity. Hence, obesity and acute inﬂammation are both
hyperresistinemic states associated with insulin resistance.
Methods
Differentiation of Primary Human Macrophages
Peripheral blood mononuclear cells were isolated from
whole blood of healthy donors following apheresis and
elutriation. Greater than 90% of these monocytes expressed
CD14 and HLA-DR. Cells were plated in 24-well plates at a
density of 10
6 cells per well, allowed to adhere for 4 h, then
washed with Dulbecco’s Modiﬁed Eagles Medium and further
cultured in 10% FBS in Dulbecco’s Modiﬁed Eagles Medium
supplemented with 5 ng/ml GM-CSF (Sigma, St. Louis,
Missouri, United States) to promote macrophage differ-
entiation. All experiments were performed after overnight
equilibration with macrophage serum-free medium (GIBCO,
San Diego, California, United States; Invitrogen, Carlsbad,
California, United States) supplemented with 5 ng/ml GM-
CSF. Cells were treated with LPS (Sigma), aspirin (Sigma),
SN50, and/or control peptide (Biomol, Plymouth Meeting,
Pennsylvania, United States), MG132, PD98059, SB20358
(Calbiochem, San Diego, California, United States), and TNFa
(R&D Systems, Minneapolis, Minnesota, United States).
Neutralizing antibodies to TNFa, IL-6, and anti-IL-1b, as well
as control IgG, were obtained from R&D Systems. Adenovirus
expressing activated IKK in pAD easy with GFP and control
vector was a generous gift from Steven Shoelson.
RNA Isolation and Quantification
RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia,
California, United States), then subjected to DNase digestion
followed by reverse transcription (Invitrogen). mRNA tran-
scripts were quantiﬁed by the dual-labeled ﬂuorogenic probe
method for real-time PCR, using a Prism 7900 thermal cycler
and sequence detector (Applied Biosystems, Foster City,
California, United States). Real-time PCR was performed
using Taqman Universal Polymerase Master Mix (Applied
Biosystems). The primers and probes used in the real-time
PCR were the following: Sense-Resistin, 59-AGCCATCAAT-
GATAGGATCCA-39; Antisense-Resistin, 59-TCCAGGC-
CAATGCTGCTTAT-39;R e s i s t i nP r o b e ,5 9-Fam-
AGGTCGCCGGCTCCCTAATATTTAGGG-TAMRA-39; Sense
human 36B4 sense, 59- TCGTGGAAGTGACATCGTCTTT-39;
Antisense 36B4, 59-CTGTCTTCCCTGGGCATCA-39;a n d
36B4 Probe, 59-FAM-TGGCAATCCCTGACGCACCG-TAM-
RA-39.
Primer and probe for TNFa were obtained from Applied
Biosystems. The cycle number at which the transcripts of the
gene of interest were detectable (CT) was normalized to the
cycle number of 36B4 detection, referred to as deltaCT. The
fold change in expression of the gene of interest in the
compound-treated group relative to that in the vehicle-
treated group was expressed as 2
 deltadeltaCT,i nw h i c h
deltadeltaCT equals the deltaCT of the compound-treated
group minus the deltaCT of the chosen control group, which
was normalized to 1.
ELISA
Resistin concentrations, in cell media and human plasma,
were assessed with a commercially available ELISA (Linco
Research, St. Charles, Missouri, United States) and normal-
ized to cell protein. The average correlation coefﬁcient for
standards using a four-parameter ﬁt was 0.99. Intra-assay and
inter-assay coefﬁcients of variance were 4.7% and 9.1%,
respectively. Direct comparison of standard curves generated
by the Linco kit with those yielded by another commercially
available resistin ELISA (Biovendor Laboratory Medicine,
Brno, Czech Republic) yielded high correlation (rho = 0.99, p
, 0.001), except that the Biovendor values were approx-
imately 30% lower than those determined with the Linco
assay. This appeared to be related to the standards used for
calibration. Discrepant absolute values among different
assays, including the Biovendor assay, were recently described
by others [22]. Resistin levels in 40 plasma samples were
measured using both Linco and Biovendor ELISA kits, with
moderate correlation (rho = 0.66). Levels of soluble TNFa
receptor 2 (sTNFR2) were measured using a commercially
available immunoassay (R&D Systems). Intra-assay and inter-
assay coefﬁcients of variance were 5.1% and 9.8%, respec-
tively.
Human Endotoxemia Study
Healthy volunteers (n = 6, three male and three female),
aged 18–45 y with BMI between 20 and 30 and on no
medications, were studied. The University of Pennsylvania
Institutional Review Board approved the study protocol, and
all participants gave written informed consent. Following
screening and exclusion of individuals with any clinical or
laboratory abnormalities, participants were admitted to the
General Clinical Research Center at the University of
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collected during the 24 h prior to and 24 h following the
intravenous administration of human-research-grade endo-
toxin (obtained from National Institutes of Health Clinical
Center, reference endotoxin [CCRE] [lots 1 and 2; National
Institutes of Health Clinical Center PDS #67801]) at a dose of
3 ng/kg given at 6 AM. Plasma and whole blood RNA (PAX
tube isolators, Qiagen) samples were isolated from blood, and
stored under appropriate conditions for subsequent assays.
Type 2 Diabetes Study
Participants with type 2 diabetes (n = 215, 167 male and 48
female), aged 35–75 y and free from clinical cardiovascular
diseases, were recruited through the diabetes clinics at the
University of Pennsylvania Medical Center and the Veterans
Affairs Medical Center, Philadelphia, Pennsylvania, to an
ongoing study of cardiovascular risk factors in type 2
diabetes. The sample was composed of 59% Caucasians and
35% African-Americans. All participants were evaluated at
the University of Pennsylvania General Clinical Research
Center in a fasting state at 8 AM. The University of
Pennsylvania Institutional Review Board approved the study
protocol, and all participants gave written informed consent.
The patient population is described in more detail elsewhere
[27].
Statistical Methods
Data are reported as mean and standard error of the mean
(SEM) for continuous variables. Because of baseline variation
in cell populations between batches of primary human
monocytes isolated from multiple donors, cell culture experi-
ments were performed in triplicate and data from represen-
tative experiments are presented. For cell culture
experiments with multiple treatments, analysis of variance
(ANOVA) was used to test for differences in means across
treatment groups. When signiﬁcant global differences were
found, post hoc t-tests were used to compare speciﬁc
treatment groups to the control. Data from the human
endotoxemia experiment were analyzed by repeated meas-
ures ANOVA. In the type 2 diabetes study, Spearman
correlations of plasma levels of resistin with plasma sTNFR2
levels are presented.
Results
Induction of Resistin Gene and Protein Expression by
Endotoxin Treatment of Human Macrophages
The regulation of resistin expression was studied in
primary cultures of human monocytic cells. Immediately
upon plating of elutriated primary human monocytes,
resistin gene expression was detectable but highly variable
from experiment to experiment (data not shown). One day
after plating, resistin gene expression remained detectable at
low levels (Figure 1A). Subjection of the cells to a protocol
leading to differentiation along the macrophage lineage led
to a modest, time-dependent enhancement of resistin gene
expression (Figure 1A). In agreement with a previous report
[28], treatment of primary macrophages with the endotoxin
LPS led to a dramatic, dose-responsive increase in resistin
gene expression (Figure 1B). We also determined that this
effect of LPS was paralleled by an increase in resistin protein
secretion into the medium (Figure 1C). Of note, activated
Figure 1. Induction of Resistin in Human Macrophages
(A) Induction of resistin during human macrophage differentiation
ex vivo. Expression of resistin on days 1, 3, and 7 following isolation
and culture of human peripheral blood monocytes under macro-
phage differentiation conditions. Results shown are the mean (6
SEM) of three separate experiments with triplicate samples. The
ANOVA F statistic for change of resistin mRNA expression during
differentiation was 7.06 (p , 0.01). *, p , 0.01 for post hoc t-tests.
(B) Resistin mRNA is induced by endotoxin in primary human
macrophage cultures. The ANOVA F statistic for change of resistin
mRNA expression in response to increasing concentration of LPS (24
h treatment) was 423.57 (p , 0.001). *, p , 0.001 for post hoc t-tests.
(C) Resistin protein secretion by human macrophages is induced by
endotoxin. The ANOVA F statistic for change of resistin protein
secretion in response to increasing concentration of LPS (24 h
treatment) was 35.36 (p , 0.001). *, p , 0.001 for post hoc t-tests.
For LPS dose response studies, shown in (B) and (C), results (mean 6
SEM) of representative experiments, with triplicate samples, are
presented. Similar results were obtained in two independent experi-
ments.
DOI: 10.1371/journal.pmed.0010045.g001
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treatment did not express detectable levels of mouse resistin,
even after treatment with LPS (data not shown).
Endotoxin Induction of Resistin Is Delayed with Respect to
TNFa
Induction of resistin gene expression by LPS exposure of
human macrophages began between 6 and 24 h after
treatment, with peak expression at 24 h (Figure 2A). This
time course of resistin induction was delayed relative to
induction of TNFa gene expression, which was detectable at 2
h and peaked 6 h after LPS exposure (Figure 2B). The
secretion of TNFa followed a similar time course (Figure 2C).
By contrast, secretion of resistin did not increase until much
later, more closely following the pattern of the appearance of
sTNFR2, a marker of TNFa action (Figure 2C) [29].
Endotoxin Induction of Resistin Is Blocked by
Immunoneutralization of Multiple Cytokines
Resistin gene expression was also induced by TNFa
treatment of primary human macrophages (Figure 3A) [28],
and resistin secretion increased in parallel (Figure 3B). Since
LPS induction of TNFa preceded the increase in resistin (see
Figure 2C), we hypothesized that TNFa, or a similar cytokine
produced early after LPS exposure, was responsible for the
later induction of resistin. Indeed, neutralizing antibodies to
TNFa markedly attenuated the increase in resistin gene
Figure 2. Endotoxin Induction of Resistin Occurs after Induction of TNFa
Primary cultures of human macrophages were treated with LPS (1 lg/
ml) for various times.
(A) Time course of induction of resistin mRNA. The ANOVA F
statistic for the change in resistin mRNA over time was 105.45 (p ,
0.001).
(B) Time course of induction of TNFa mRNA. The ANOVA F statistic
was 34.57 (p , 0.001).
(C) Time course of secretion of resistin, TNFa, and sTNFR2 into
medium. ANOVA F statistics for the effect of LPS on resistin (66.51, p
, 0.001), sTNFR2 (12.86, p , 0.001), and TNFa (20.48, p , 0.001) were
highly signiﬁcant. Maximal secreted protein levels were as follows:
resistin, 21.9 ng/ml/mg; TNFa, 207.2 ng/ml/mg; and sTNFR2, 39.3 ng/
ml/mg. Results of representative experiments with triplicate samples
are expressed as mean (6 SEM). Similar results were obtained in
three independent experiments.
DOI: 10.1371/journal.pmed.0010045.g002
Figure 3. Endotoxin-Induced Cytokines Regulate Resistin Induction
(A) TNFa induces production of resistin mRNA by primary human
macrophages. The ANOVA F statistic for the effect of increasing
TNFa concentrations on resistin was 23.81 (p , 0.001). *, p , 0.001
for post hoc t-tests.
(B) TNFa induces resistin protein secretion by primary human
macrophages. ANOVA F statistic for the effect of TNFa on resistin
was 79.85 (p , 0.001). *, p , 0.005 for post hoc t-tests. Results of
representative experiments with triplicate samples are expressed as
the mean (6 SEM). Similar results were obtained in two independent
experiments.
(C) LPS (1 lg/ml) induction of resistin is abrogated by antibody
neutralization of cytokines (7.5 lg/ml per antibody). ANOVA F
statistic for the effect of neutralizing antibodies on resistin was 3.08 (p
, 0.05). p-Values for post hoc t-tests versus IgG: *, p , 0.05; **, p ,
0.001. Results are expressed as the mean (6 SEM) of three separate
experiments with triplicate samples.
DOI: 10.1371/journal.pmed.0010045.g003
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cytokines, including IL-6 and IL-1b [30], and IL-6 induces
resistin modestly (data not shown) [28]. Antibodies to IL-6
and IL-1b individually had minor effects on LPS stimulation
of resistin (Figure 3C). However, the combination of anti-
bodies to TNFa, IL-6, and IL-1b markedly attenuated LPS
induction of resistin (Figure 3C). These data clearly show that
resistin induction by endotoxin is mediated by a cascade in
which the primary event is secretion of inﬂammatory
cytokines that, in turn, induce resistin.
Induction of Resistin Is Blocked by Anti-Inflammatory
Insulin-Sensitizing Drugs That Target NF-jB
Mouse resistin, produced exclusively by adipocytes, is
down-regulated by antidiabetic thiazolidinediones, including
rosiglitazone [11]. Consistent with an earlier report [16],
rosiglitazone down-regulated resistin gene expression (Figure
4A) in LPS-stimulated human macrophages. Resistin protein
secretion was also signiﬁcantly reduced by rosiglitazone
(Figure 4B). Hence, macrophage expression of resistin and
its induction by LPS is species-speciﬁc, but down-regulation
of resistin by thiazolidinedione occurs both in rodents and
humans. Rosiglitazone has marked anti-inﬂammatory effects
on macrophages [31]. This led us to examine the effect of
aspirin, an anti-inﬂammatory compound that targets IjB
kinase and has insulin-sensitizing effects [32]. Remarkably,
aspirin dramatically decreased endotoxin-induced resistin
expression in a dose-dependent manner (Figure 4C). Both
aspirin (via IjB kinase) and rosiglitazone (via PPARc) inhibit
NF-jB [31,32], which is activated by LPS. Indeed, treatment of
the macrophages with the proteasome inhibitor MG132,
which prevents NF-jB activation [33], abrogated endotoxin-
induced activation of resistin expression (data not shown).
Moreover, treatment of the macrophages with SN50, a cell-
permeable peptide that speciﬁcally prevents activation of NF-
jB by inhibiting its nuclear translocation [34], nearly
abolished endotoxin-induced activation of resistin expression
(Figure 4D). Thus, activation of NF-jB is required for LPS
induction of resistin in human macrophages. Furthermore,
constitutive activation of NF-jB by adenoviral expression of
activated IjB kinase was sufﬁcient to induce resistin in
primary human macrophages (Figure 4E). The magnitude of
this activation was less than that caused by LPS, which is
known to also activate MAP-kinase (MAPK). Indeed, inhib-
ition of either p42 MAPK by PD98059, or p38 MAPK (using
SB20358) partially blocked the induction of resistin by LPS
(Figure 4F). Together these results show that NF-jB activation
is necessary and sufﬁcient for resistin induction by LPS, with
MAPK activation increasing the magnitude of the response.
LPS Robustly Increases Circulating Resistin Levels in
Healthy Humans
Next, we asked whether our ﬁndings from ex vivo studies of
human macrophages would translate into in vivo observa-
tions in humans. Six healthy volunteers were injected with
LPS, using a protocol similar to that shown to produce insulin
resistance [35]. Baseline circulating resistin levels were
approximately 4 ng/ml, and remained relatively constant for
several hours prior to LPS infusion (Figure 5A). Remarkably,
resistin levels rose dramatically because of endotoxemia,
peaking 8–16 h after LPS administration (Figure 5A). The
time course of hyperresistinemia paralleled the increase in
Figure 4. Inhibition of Resistin Induction by Anti-Inflammatory Insulin
Sensitizers
(A) Down-regulation of resistin mRNA by rosiglitazone. ANOVA F
statistic for the effect Rosiglitazone on resistin expression was 62.52
(p , 0.001). p value for post hoc t-tests, is depicted in the Figure. *p ,
0.005 versus control for post hoc t-tests.
(B) Down-regulation of resistin protein secretion by human macro-
phagestreatedwithrosiglitazone.TheANOVAFstatisticfortheeffect
of rosiglitazone on resistin protein secretion was 29.44 (p , 0.001). p-
Valuesforposthoct-testsversuscontrol:*,p,0.05;**,p,0.001.Cells
werepre-treatedwithrosiglitazone for24hand withLPS(1 lg/ml)and
rosiglitazone for an additional 24 h. Results of representative experi-
ments with triplicate samples are expressed as mean (6 SEM). Similar
results were obtained in three independent experiments.
(C) Down-regulation of resistin gene expression by aspirin. The
ANOVA F statistic for the effect of aspirin on resistin expression was
61.33 (p , 0.001). p-Values for post hoc t-tests versus no aspirin: *, p ,
0.01; **, p , 0.001; ***, p , 0.0001. Cells were pre-treated with
aspirin for 2 h and with LPS (1 l g/ml) and aspirin for an additional
24 h. Results of representative experiments with triplicate samples
are expressed as mean (6 SEM). Similar results were obtained in two
independent experiments.
(D) Down-regulation of resistin gene expression by NF-jB inhibitor
SN50. *, p , 0.001 versus control peptide by t-test. Cells were pre-
treated with SN50 or control peptide at 100 ug/ml for 2 h, and with
LPS (1 lg/ml) and SN50 or control peptide for an additional 24 h.
Results are the expressed as the mean (6 SEM) of two independent
experiments performed in triplicate.
(E) Induction of resistin by activation of NF-jB. *, p , 0.05 versus
control virus by t-test. Cells were infected with adenovirus expressing
activated IKK or control virus for 24 h. Results of representative
experiments with triplicate samples are expressed as mean (6 SEM).
Similar results were obtained in two independent experiments.
(F) Down-regulation of resistin gene expression by inhibitors of p38
and p42 MAPK. The ANOVA F statistic for the effect of the MAPK
inhibitoronresistinexpressionwas11.54(p,0.005).*,p,0.005versus
control for post hoc t-tests. Cells were pretreated with 50 lM PD98059
or 2.5 lM SB20358 for 2 h and with LPS (1 lg/ml) and PD98059 or
SB20358 for an additional 24 h. Results are expressed as the mean (6
SEM) of two independent experiments performed in triplicate.
DOI: 10.1371/journal.pmed.0010045.g004
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levels was more marked and sustained (Figure 5A). The
increase in resistin protein levels correlated with increased
resistin gene expression in peripheral blood mononuclear
cells following systemic endotoxemia (Figure 5B).
Circulating Resistin Levels Correlate with the
Inflammatory Marker sTNFR2 in Patients with Type 2
Diabetes
Patients with type 2 diabetes and insulin resistance, many
of whom are obese, have elevated levels of several inﬂamma-
tory markers, including IL-6, TNFa, and sTNFR2 [36]. LPS
administration has been shown to induce acute insulin
resistance in humans [37]. Given that LPS infusion increased
resistin levels, we measured resistin in a cohort of 215
patients with type 2 diabetes. Circulating resistin levels were
signiﬁcantly correlated with levels of sTNFR (Figure 6A).
Thus, there is an association between resistin levels and
systemic inﬂammation in patients with type 2 diabetes.
Discussion
We have demonstrated that, in human macrophages, an
inﬂammatory cascade with secretion of cytokines, including
TNFa and IL-6, is sufﬁcient and necessary for the induction
of resistin. Insulin sensitizers that have anti-inﬂammatory
properties, including a synthetic PPARc agonist as well as
aspirin, suppress macrophage resistin expression, as does
direct inhibition of NF-jB. Experimental endotoxemia in
healthy volunteers, based on the well-established gram-
negative bacterial inﬂammatory response in humans
[38,39,40], induces a dramatic elevation of circulating resistin
levels. Hence, resistin gene and protein expression are
increased by inﬂammatory stimuli both ex vivo and in vivo.
In rodents, resistin is produced exclusively by adipocytes,
regulates normal glucose homeostasis, and causes insulin
resistance at high circulating levels [11,13]. Translation of
resistin’s metabolic effects from rodents to humans has been
problematic because peripheral blood mononuclear cells and
macrophages appear to be a primary source of resistin in
humans [15,16]. This species difference in primary locus of
expression is yet another example of the close and function-
ally overlapping relationship between adipocytes and macro-
phages [41]. Numerous studies have reported that circulating
resistin levels are increased in human obesity [20,25,26,41]
and diabetes [19,20,23,42,43]. Our data suggest that, whereas
hyperresistinemia in obese rodents derives directly from
adipocytes, human resistin is indirectly regulated by the
inﬂammatory internal milieu of obesity (Figure 6B). Indeed,
obesity is associated with elevated levels of cytokines whose
systemic administration leads to impaired glucose homeo-
stasis [36,44,45], such as TNFa and IL-6, which we show here
to mediate the inﬂammatory induction of human resistin.
Thus, in both species, adipose tissue is an endocrine organ
containing adipocytes as well as macrophages that regulates
energy metabolism and glucose homeostasis through secre-
tion of multiple factors, including inﬂammatory cytokines
[46].
Clearly the relationship between obesity, inﬂammation,
and resistin expression is complex, and needs to be system-
atically studied in larger and varied patient populations.
Intriguingly, we found a strong correlation between plasma
levels of resistin and sTNFR2, the soluble cleavage product of
the activated TNFa receptor, in diabetic patients. A com-
parable correlation between resistin and sTNFR2 (R = 0.31, p
, 0.001) was found in a cohort of 879 non-diabetic
individuals, in whom resistin levels independently correlated
with coronary atherosclerotic disease (M. P. Reilly, M. Lehrke,
M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader,
unpublished data).
LPS binds to pathogen-associated-molecular-pattern in-
nate immune receptors, such as CD14 and Toll-like receptor
4, activating signal cascades involving NF-jB and MAPK [47]
and thereby inducing the transcription and secretion of early
cytokines, including TNFa and IL-1 [48]. We have shown here
that these early cytokines are responsible for secondary
induction or enhancement of resistin expression in macro-
phages. Hyperresistinemia impairs glucose homeostasis in
rodents [49,50], and inﬂammatory states are associated with
insulin resistance [36], which may serve as a physiological
attempt to increase the provision of glucose to the brain
under stress conditions. Indeed, induction of acute inﬂam-
Figure 5. Endotoxin Dramatically Induces Plasma Resistin in Humans
(A) Plasma resistin and sTNFR2 levels were measured serially in six
healthy volunteers for 24 h before and after intravenous LPS (3 ng/kg)
administration. The repeated measures ANOVA F statistics for the
effect of LPS on plasma resistin (9.25, p , 0.001) and sTNFR2 (23.65, p
, 0.001) were highly signiﬁcant.
(B) Mean resistin RNA expression in whole blood cells of healthy
volunteers (n = 2) before and after treatment with LPS (3 ng/kg).
DOI: 10.1371/journal.pmed.0010045.g005
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humans [37], and here we have demonstrated the concom-
itant induction of resistin. Interestingly, the peak in TNFa
and IL-6 levels after LPS administration to humans precedes
a phase of prolonged insulin resistance that begins approx-
imately 6 h after LPS administration [37], closely approx-
imating the time course of resistin induction. Hence resistin
is a potential mediator of insulin resistance in humans with
acute inﬂammation. Moreover, obesity is associated with
activation of innate immunity [6], including the inﬂammatory
mediators that induce resistin. In this context it is intriguing
that resistin levels are increased in obesity [25,26] and that
insulin-sensitizing agents such as aspirin and rosiglitazone,
with disparate primary molecular targets, antagonize resistin
induction. Indeed, thiazolidinedione suppression of resistin
levels has recently been correlated with hepatic insulin
sensitization [43]. Future work will be needed to better
understand the relationship between circulating resistin
levels and the insulin resistance characteristic of inﬂamma-
tory states, including obesity.
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Patient Summary
Why Was This Study Done? There is a very close connection between
obesity and diabetes: diabetes is more common among obese people,
and people with type 2 diabetes know that weight control is an essential
part of their diabetes treatment. But the link between extra body fat and
diabetes remains a puzzle. Recent experiments in mice suggested that a
hormone called resistin could be the missing link. One reason is that
resistin levels respond to a particular class of diabetes drugs called
thiazolidinediones. But studies in humans found that mice and humans
are quite different when it comes to resistin. One difference is that in
mice resistin is produced by fat cells, but in humans it is produced by
special immune cells called macrophages that are involved inflamma-
tion. Researchers are now studying what role—if any—resistin might
have in humans with obesity and diabetes and are studying the
similarities in the ways in which the body reacts to obesity and
inflammation.
What Did the Researchers Do? The researchers examined what
happens to resistin levels when human macrophages or human patients
are exposed to substances that trigger inflammation.
What Did They Find? The substances that trigger inflammation caused
higher resistin levels, but resistin levels were lowered again by
thiazolidinediones.
What Does This Mean? Because in mice higher resistin levels (produced
by fat cells) are linked to diabetes, one possibility is that obesity in
humans, by being similar to inflammation, causes immune cells to make
lots of resistin and hence promotes diabetes that way.
What Next? More research is necessary to confirm these findings and to
find out how important resistin is as a link between obesity and diabetes,
and how resistin promotes diabetes.
Additional Information. United States National Institute of Diabetes,
Digestive, and Kidney Diseases (NIDDK) information on obesity: http://
www.niddk.nih.gov/health/nutrit/pubs/unders.htm
NIDDK information on diabetes: http://diabetes.niddk.nih.gov/
International Diabetes Federation: http://www.idf.org/
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